Catapult Capital Management’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Catapult Capital Management’s Portfolio SLXP Stock Details SLXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-10,000	Closed	-$1.04M	–	288
2014 Q1	$1.04M	Buy	+10,000	New	+$1.02M	0.21%	110
2013 Q4	–	Sell	-30,000	Closed	-$2.01M	–	306
2013 Q3	$2.01M	Sell	30,000 -15,000	-33%	-$1.03M	0.25%	128
2013 Q2	$2.98M	Buy	+45,000	New	+$2.57M	1.24%	17

Other funds holding SLXP

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Catapult Capital Management's SLXP Position: Q2 2014 in Review

Catapult Capital Management sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q2 2014, closing a stake of 10,000 shares — an estimated $1.04M sold.

Catapult Capital Management first reported a position in SLXP in Q2 2013 and held it in 3 quarters. The position peaked at $2.98M in Q2 2013. 308 funds tracked by Wall St. Rank hold SLXP as of Q2 2014.

Catapult Capital Management reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q2 2014 after selling out during the quarter.
Catapult Capital Management sold 10,000 SALIX PHARMACEUTICALS LTD DEL shares in Q2 2014, an estimated $1.04M.
Catapult Capital Management first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q2 2013 and held it in 3 quarters.
Catapult Capital Management's SALIX PHARMACEUTICALS LTD DEL position peaked at $2.98M in Q2 2013.
308 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q2 2014.

Based on Catapult Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.